Furthermore, we present clear indication that low levels of ATR in tumor cells as well as their adjacent stromal fibroblasts predict high risk of recurrence and poor survival post-neoadjuvant treatment of locally advanced breast cancer patients. This evidence concerns the gene ATR and neoplasm.